Enadenotucirev Clinical

A Phase 1 Dose Escalation Study of the Oncolytic Adenovirus Enadenotucirev, Administered Intravenously to Patients with Epithelial Solid Tumors (EVOLVE)

Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey, Ignacio Duran, Luc Dirix, Karen Geboes, Christine Wilkinson-Blanc, Gillian Pover, Simon Alvis, Brian Champion*, Kerry Fisher, Hilary McElwaine-Johnn, John Beadle and Emiliano Calvo. Journal for ImmunoTherapy of Cancer (2019) 7:20

Kate WrightEnadenotucirev Clinical

Phase 1 Study of Intravenous Administration of the Chimeric Adenovirus Enadenotucirev in Patients Undergoing Primary Tumor Resection

Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada JM, Boni V, Blanc C, Seymour L, Beadle J, Alvis S, Champion B, Calvo E, Fisher K.  
Journal for ImmunoTherapy of Cancer2017 5:71

Nitin JainEnadenotucirev Clinical
Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image
Menu